SCHEMBL17447121

SCHEMBL17447121

NCCCC[C@H](N)C(=O)NCC(=O)OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.60
LTA4H P09960 1/20 0.58
ANPEP P15144 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
ABCC3 O15438 1/20 0.49
NR1I2 O75469 1/20 0.49
ABCB11 O95342 1/20 0.49
NR3C1 P04150 1/20 0.49
RARG P13631 1/20 0.49
CNR1 P21554 1/20 0.49
OPRK1 P41145 1/20 0.49
NR1H2 P55055 1/20 0.49
PPARA Q07869 1/20 0.49
NR1H3 Q13133 1/20 0.49
NR1I3 Q14994 1/20 0.49
TERT O14746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18567745 1.00 MMP2 (0.60) MMP2LTA4HANPEPCYP1A2CYP3A4
SCHEMBL24234674 0.91 MMP2 (0.54) MMP2LTA4HANPEPCYP1A2CYP3A4
SCHEMBL18791194 0.89 CPB1 (0.57) MMP2LTA4HANPEPCPB1CPB2
Hydrochloric Acid SCHEMBL10654766 0.86 ANPEP (0.64) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL29849264 0.86 CYP1A2 (0.52) LTA4HANPEPCYP1A2CYP3A4CYP2D6
SCHEMBL12668303 0.85 ANPEP (0.61) ANPEPDPP8DPP7DPP4DPP9
SCHEMBL19871881 0.85 SIRT2 (0.55) MMP2LTA4HANPEPDPP8DPP7
SCHEMBL16217828 0.85 SIRT2 (0.55) MMP2LTA4HANPEPDPP8DPP7
SCHEMBL7760121 0.85 LTA4H (0.56) LTA4HCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL14864739 0.84 CYP1A2 (0.50) LTA4HCYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10947289-B2 Glyco-modified atrial natriuretic peptide DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-03-16 US disclosed
US-20210040170-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2021-02-11 US disclosed
EP-2949665-B1 GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO CO LTD (JP) 2018-02-28 EP disclosed
US-20160017015-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10947289-B2 Glyco-modified atrial natriuretic peptide NPPA, NPR1, NPR3 MMP2 936/4885LTA4H 3292/4885ANPEP 9/4885
US-20210040170-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE NPPA, NPR1, NPR3 MMP2 936/4885LTA4H 3292/4885ANPEP 9/4885
US-20160017015-A1 GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE NPPA, NPR1, NPR3 MMP2 936/4885LTA4H 3292/4885ANPEP 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.